Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872401 · ClinicalTrials.gov registry record · Phase 3
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,301
- Enrollment target
NCT03872401 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 12,301 participants.
The verdict
NCT03872401, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,301 participants
- Enrollment target
Study Summary
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Interventions
- DRUG Placebo
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,301 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2025-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03872401
The ClinicalTrials.gov registry entry for NCT03872401 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03872401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03872401 about?
NCT03872401 is a clinical study titled "Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke". This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
What is the current status of trial NCT03872401?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,301 participants. The study started on 2019-06-11. Estimated completion is 2025-07-25.
What interventions are being tested in trial NCT03872401?
The interventions under investigation include: Placebo (DRUG), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03872401?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.